Introduction {#Sec1}
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Coronavirus disease 2019 (COVID-19), a disease caused by the novel betacoronavirus (SARS-CoV-2), has become a pandemic threat leading to more than 4,170,000 confirmed cases and 287,399 deaths globally, as declared by the World Health Organization (WHO) on May 13th, 2020. Although the most common symptoms of COVID-19 are fever and cough, a number of patients have experienced neurological manifestations such as headache, dizziness, hypogeusia and hyposmia during the course of the illness \[[@CR1]--[@CR4]\]. In addition, patients requiring intensive care unit (ICU) care were more likely to have underlying comorbidities such as cerebrovascular disease (CVD), hypertension, cardiovascular disease, diabetes, or cancer than patients who did not require ICU care \[[@CR3]\]. Furthermore, it has been found that the receptor-binding domain of SARS-CoV-2 is similar to that of SARS-CoV, the virus that is responsible for the pandemic infectious disease---severe acute respiratory syndrome (SARS)---happened in 2002 and 2003 \[[@CR5]\]. SARS-CoV-2 binds to the angiotensin-converting enzyme 2 (ACE2) receptor to access human cells, as does SARS-CoV \[[@CR5]\]. Therefore, cells expressing ACE2 may act as targets and thus are vulnerable to SARS-CoV-2 infection. Specifically, it has also been reported that glial cells and neurons, in addition to endothelial and arterial smooth muscle cells in the brain express ACE2 receptors, which renders them potential targets of SARS-CoV-2 \[[@CR6]--[@CR8]\]. Such evidence indicates potential neurotropic involvement of SARS-CoV-2 \[[@CR8]--[@CR10]\]. It is therefore of great importance to investigate its neurotropic effects and to understand the underlying mechanisms. Thus, we have reviewed the neurological characteristics of COVID-19 and summarized possible mechanisms of SARS-CoV-2 involvement in the central nervous system (CNS).

Neurological manifestations of COVID-19 {#Sec2}
=======================================

Increasing evidence indicates that coronaviruses may invade the CNS, causing neurological disorders. Headache has been the most common neurological manifestation reported by COVID-19 patients \[[@CR1], [@CR2]\]. A systematic review of 554 COVID-19 patients concluded that the mean prevalence of headache was 8% (95% CI 5.7--10.2%) \[[@CR11]\]. Apart from headache, dizziness is also a common neurological manifestation of COVID-19, with a reported prevalence of between 7 and 9.4% \[[@CR3], [@CR12]\]. Of 138 hospitalized patients, those who required ICU care (*n* = 36) were more likely to report dizziness than those who did not (*n* = 102) (ICU 8/36 \[22.2%\] vs non-ICU 5/102 \[4.9%\], *P* = 0.007) \[[@CR3]\]. Confusion and headache were the fifth (9/99 \[9%\]) and sixth (8/99 \[8%\]) most common symptoms of the 99 COVID-19 patients at admission, respectively \[[@CR13]\]. Furthermore, it has recently been reported that a number of cases of COVID-19 have had concurrent severe neurological symptoms, such as acute CVD (acute ischemic stroke, cerebral venous sinus thrombosis, cerebral hemorrhage, subarachnoid hemorrhage), meningitis/encephalitis, acute necrotizing hemorrhagic encephalopathy, and acute Guillain--Barré syndrome \[[@CR14]--[@CR19]\].

It is worth noting that the prevalence of neurological manifestations was higher in a report by Ling et al*.* who paid more attention to the neurological manifestations of COVID-19 than the aforementioned studies. Of the 214 COVID-19 patients in that report, 78 (36.4%) patients had neurological manifestations. Compared with non-severe patients, severe patients were more likely to have neurological symptoms (40 \[45.5%\] vs 38 \[30.2%\], *P* \< 0.05), such as acute CVD (5 \[5.7%\] vs 1 \[0.8%\], *P* \< 0.05), impaired consciousness (13 \[14.8%\] vs 3 \[2.4%\], *P* \< 0.001) or skeletal muscle injury (17 \[19.3%\] vs 6 \[4.8%\], *P* \< 0.001). The most common neurological manifestation was dizziness (36 \[16.8%\]), followed by headache (28 \[13.1%\]), impaired consciousness (16 \[7.5%\]), acute CVD (6 \[2.8\]), ataxia (1 \[0.5%\]) and seizure (1 \[0.5%\]). In addition, symptoms involving the cranial nerves, such as hypogeusia, hyposmia, hypopsia, and neuralgia have also been reported in 19 (8.9%) patients \[[@CR4]\]. The reason for the difference in incidence of different neurological manifestations between the various reports remains unclear. One possible factor maybe because of the little we know about COVID-19. Because it is a recently identified disease, COVID-19 has been principally identified by its prominent symptoms such as fever, cough, and dyspnea and not the less common neurological manifestations such as headache, dizziness, and chemosensitive impairment \[[@CR20]\]. An analysis of the course of illness has provided evidence that smell and taste impairment are early manifestations of COVID-19, usually appearing in the first 5 days of illness. Ageusia and anosmia were the first symptoms of disease in a number of patients \[[@CR21]\]. As recognition of the disease having developed, the reported incidence of chemosensitive impairment in COVID-19 has been considerably higher than in the initial stages, ranging from 19.4 to 88% \[[@CR20]--[@CR23]\]. In addition, as stated by Bookstaver and collaborators, the clinical symptoms of viral infection are usually nonspecific and sometimes may be mild or symptomless \[[@CR24]\]. Therefore, the prevalence of neurological manifestations was very likely underestimated in the early stages of the COVID-19 outbreak \[[@CR21], [@CR23]\].

CVD is among the most prevalent comorbidities of COVID-19 patients, especially in severe cases. Chen et al*.* reported that cardiovascular and cerebrovascular diseases were the most prevalent (40/99 \[40%\]) chronic underlying conditions \[[@CR13]\]. Of the reported 138 hospitalized patients, CVD (7/138, 5.1%) ranked fifth among the most common comorbidities, while the first to fourth comorbidities were hypertension (43/138, 46.4%), cardiovascular disease (20/138, 14.5%), diabetes (14/138, 10.1%) and cancer (10/138, 7.2%). ICU patients were also more likely to have CVD than non-ICU patients (ICU 6/36 \[16.7%\] vs non-ICU 1/102 \[1.0%\], *P* = 0.001) \[[@CR3]\]. In addition, CVD and coronary heart disease have been confirmed to be independent risk factors associated with fatal outcome \[[@CR25]\]. These observations are understandable as the majority of the reported COVID-19 patients have been elderly (age ≥ 50 years old, 70%) \[[@CR26]\] who are statistically more likely to have comorbidities and thus more likely to progress into severe cases \[[@CR27]\].

Neurotropic evidence of SARS-CoV-2 {#Sec3}
==================================

On January 3rd, 2020, the first complete genome of SARS-CoV-2, the novel coronaviruses that resembles SARS-CoV, was sequenced from a sample of bronchoalveolar lavage fluid of a patient from Wuhan \[[@CR28]\]. SARS-CoV-2 is a single-stranded RNA coronavirus the genome of which has 89.1% similarity in its nucleotide sequence to a group of SARS-like coronaviruses. It has been classified as the genus Betacoronavirus, subgenus Sarbecovirus and is the seventh member of the coronavirus family that can infect humans. Of these, four human coronaviruses, NL63, HKU1, 229E, and OC43 typically cause common cold symptoms, while the remaining three are responsible for a number of pandemic infectious diseases, including SARS in 2002 and 2003 (SARS-CoV), MERS in 2012 (MERS-CoV) and COVID-19 (SARS-CoV-2) \[[@CR5], [@CR29]\].

Up to now, there is sparse direct evidence of the neurotropism of SARS-CoV-2. However, it has been found that the viral structure as well as the receptor-binding domain of SARS-CoV-2 are similar to that of SARS-CoV. Both SARS-CoV-2 and SARS-CoV bind to the ACE2 receptor to access human cells \[[@CR5]\]. Therefore, evidence previously found for SARS-CoV may also apply to SARS-CoV-2. A considerable number of studies have provided strong evidence for the neurovirulence of SARS-CoV. Apart from neurological manifestations reported by SARS patients \[[@CR30]\], SARS-CoV was detected in samples or specimens of SARS patients. CSF samples of a SARS patient who presented generalized tonic--clonic convulsion tested positive for SARS-CoV, suggesting possible infection of the CNS by SARS-CoV \[[@CR31]\]. Jun et al*.* isolated SARS-CoV from a specimen of brain tissue of a patient with SARS that had presented severe CNS symptoms. Pathological examination of the brain tissue indicated neuronal necrosis and glial cell hyperplasia \[[@CR32]\]. Furthermore, SARS viral particles and its genomic sequence were detected in the neurons in the brains of all eight confirmed cases of SARS autopsies. Of these, six confirmed cases presented edema and scattered red degeneration of the neurons \[[@CR33]\]. Animal models also provided evidence of SARS-CoV being neurotropic. The results suggested that the brain was the principal target organ for SARS-CoV in the mice transgenic for human ACE2 (*hACE2* mice) \[[@CR34]\]. SARS-CoV enters the brain mainly through the olfactory bulb and rapidly spreads transneuronally to other related zones of the brain. This widespread neuronal infection and the concomitant neuronal loss, except for lung infection, account for the major cause of death in *hACE2* mice \[[@CR35]\]. These findings of neurovirulence in SARS-CoV could provide circumstantial evidence of the neurotropic characteristics of SARS-CoV-2.

In addition, several reports have provided evidences to the neurotropism of SARS-CoV-2. For instance, neurological symptoms, such as headache, dizziness, and impaired consciousness as well as symptoms involving the cranial nerves (hypogeusia, hyposmia, hypopsia, and neuralgia) have been reported in COVID-19 patients \[[@CR2], [@CR4], [@CR20], [@CR22], [@CR23]\]. Importantly, the neurological manifestations presented by COVID-19 patients have been nonspecific and difficult to differentiate from encephalopathy induced by systemic viremia occurring outside the CNS \[[@CR36]\]. Elderly patients with chronic underlying medical conditions are at increased risk of encephalopathy in the setting of acute infections. In addition, COVID-19 patients, especially severe cases, frequently present severe systemic manifestations such as hypoxia, viremia, cytokine storm and coagulopathy which can induce encephalopathy in addition to the direct effects of SARS-COV-2 \[[@CR3], [@CR37], [@CR38]\]. A series of case reports have reported that COVID-19 patients presenting with headache, altered mental status, acute CVD, acute necrotizing hemorrhagic encephalopathy, and acute Guillain--Barré syndrome but without abnormal cerebrospinal fluid (CSF) analysis, which indicates that SARS-CoV-2 does not cross the blood--brain barrier (BBB) and does not cause meningitis or encephalitis \[[@CR14]--[@CR18], [@CR39], [@CR40]\]. Although a direct association between the aforementioned symptoms of encephalopathy and COVID-19 requires further investigation, COVID-19 should be considered first when conducting differential diagnosis during the pandemic because of the probable risk of transmission as a result of missed diagnosis.

Recently, Takeshi et al*.* reported the first case of meningitis/encephalitis associated with SARS-CoV-2. They detected SARS-CoV-2 RNA in the CSF specimen \[[@CR19]\], providing direct evidence of the neuroinvasiveness of SARS-CoV-2. In addition, the pathological findings of brain tissue in COVID-19 patients have been reported in the gross anatomy of a patient admitted because of cerebral infarction and diagnosed as having COVID-19 on the 13th day of admission. Only nonspecific brain edema and atrophy without further histopathological observations were found by gross anatomical examination of this patient and without any signs of infection \[[@CR41]\]. Thus, detailed neurological examination and attempts to separate SARS-CoV-2 from the neuronal tissue are required to provide direct neurotropic evidence of SARS-CoV-2 \[[@CR8]\].

Potential neurotropic mechanisms of SARS-CoV-2 {#Sec4}
==============================================

The underlying neurotropic mechanisms of SARS-CoV-2 have yet to be established. However, the neurotropic mechanisms previously found in SARS-CoV and other viruses may serve as a reference for SARS-CoV-2.

There are essentially two principal routes for viruses to gain entry into the CNS: hematogenous or neuronal retrograde dissemination \[[@CR36], [@CR42], [@CR43]\]. In hematogenous entry, a virus can infect endothelial cells of the BBB to gain access or infect leukocytes for dissemination into the CNS \[[@CR36], [@CR42], [@CR43]\]. It has been speculated that SARS-CoV infects endothelial cells of the BBB following viremia, allowing direct passage across the BBB into the CNS \[[@CR44]\]. SARS-CoV-2 may also bind to ACE2 expressed in the capillary endothelium of BBB to gain access into the CNS \[[@CR8]\]. On the other hand, it has also been found that SARS-CoV can infect monocytes and macrophages to migrate through the BBB \[[@CR33]\].

As a second major route of entry to the CNS, some viruses infect neurons in the periphery and use the axonal transport machinery to enter the CNS \[[@CR36], [@CR42], [@CR43]\]. This could represent another potential route of entry to the CNS for SARS-CoV-2, that is via the cranial nerve. ACE2 is widely expressed on the epithelial cells of the oral mucosa \[[@CR45]\]. Moreover, the olfactory nerve serves as a shortcut for many viruses into the CNS \[[@CR46]\]. Olfactory receptor neurons project dendrites into the nasal cavity and extend axons through the cribriform plate into the olfactory bulb of the brain \[[@CR46]\]. It has been reported that nasopharyngeal swabs of multiple patients have tested positive \[[@CR47], [@CR48]\], and the major route of transmission of SARS-CoV-2 is via the respiratory tract through the nose. Meanwhile, hyposmia and hypogeusia are neurological manifestations reported in some cases \[[@CR4], [@CR20], [@CR22], [@CR23]\]. Furthermore, it has been found that SARS-CoV enters the brains of *hACE2* mice mainly through the olfactory bulb, resulting in rapid, transneuronal spread to related areas of the brain \[[@CR35]\]. This evidence could partly explain the plausible mechanism of cranial nervous system symptoms in COVID-19.

In addition to the direct infection injury of SARS-CoV-2 to the CNS, SARS-CoV-2 may indirectly affect the CNS \[[@CR10]\]. In published reports of SARS-CoV-2, a cytokine storm, elevated D-dimer levels, and thrombocytopenia have been reported \[[@CR38], [@CR49]\]. Intracranial cytokine storms, which could result in the breakdown of the BBB without direct viral invasion, might be responsible for the development of acute necrotizing encephalopathy or Guillain--Barré syndrome \[[@CR16], [@CR17]\]. Coagulopathy observed in COVID-19, together with a cytokine storm, could render patients prone to cerebrovascular events, both thrombotic and hemorrhagic \[[@CR18]\].

Conclusions {#Sec5}
===========

Both the structural basis of SARS-CoV-2 and several indirect and direct evidence mentioned above have provided proof to support the theory of neurotropic involvement of SARS-CoV-2. Thus, considerably more attention should be paid to the risk of neurological involvement in patients with COVID-19. We must keep the diagnosis of SARS-CoV-2 infection in mind when patients presented specific or nonspecific neurological symptoms during the pandemic.
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